Navigation Links
Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBC's Drug Discovery & Development of Innovative Therapeutics Conference

WESTBOROUGH, Mass. June 30 /PRNewswire/ -- Joseph B. Bolen, Ph.D., CSO of Millennium Pharmaceuticals, will chair the Focus on Cancer track IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition taking place August 4-7 at the World Trade Center Boston & Seaport Hotel in Boston, MA. The cancer track presentations will focus on therapies for Hematology, Lung Cancer, Blood Borne Cancers, and Clinical Biomarkers.

Bolen has confirmed academia speakers including: Kenneth C. Anderson, M.D., Dana Farber Cancer Institute, Harvard Medical School; Bruce E. Johnson, M.D., Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital; Mark A. Israel, M.D., Dartmouth Medical School; Neal Rosen, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center; Massimo Loda, M.D., Dana Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School

Companies also giving technical conference presentations in this cancer track include Alnylam Pharmaceuticals, Amgen, Inc., ARIAD Pharmaceuticals Inc., ArQule, Inc., AstraZeneca R&D Boston, Bristol-Myers Squibb Company, Exelixis Inc, Genzyme Corporation, Infinity Pharmaceuticals, Inc, Merck Research Laboratories, Novartis Institutes for BioMedical Research, OncoMed Pharmaceuticals Inc, The Johnson & Johnson Family of Companies.

Additional conference sessions at Drug Discovery & Development of Innovative Therapeutics conference include:

-- Cardio-Metabolic Disease Drug Discovery and Development

-- Translational Medicine/Research

-- Transforming Technologies

-- Anti-Infective Drug Discovery and Development

-- Neurodegenerative Disease Drug Discovery and Development

-- Inflammation in Drug Discovery and Development

-- Orphan Diseases: Fast-Tracking Orphan Drugs and Scientific Advances -- The Next Generation of Therapeutics: Emerging Biologics, Stem Cells and RNAi

IBC's Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition is an international event that covers topics across multiple therapeutic areas. The event includes over 15 presentations from more than 200 speakers, 150 exhibitors, 13 interactive round table discussions and 4 keynote presentations. For more information please visit

Complete details on this event can be found at or to receive a press pass or arrange an interview with a speaker, email Keri Dostie at

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit:

Contact: Keri Dostie

IBC Life Sciences


SOURCE IBC Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
3. SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors
4. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
5. J. Craig Venter Institute Names Robert Friedman, Ph.D., Deputy Director of West Coast Facility
6. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
7. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
8. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
9. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
10. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):